Forbes – Martin Shkreli, the 29-year old founder of MSMB Capital in New York, is best known to investors as an activist who battled billionaires and entrenched drug industry executives through blog posts, shareholder letters, regulatory filings, and even an attempted hostile takeover.
But now Shkreli says that he is giving the fund’s money back to investors to focus on a new effort: a startup, called Retrophin, of which he is chief executive. The company is getting ready to start a clinical trial of its most advanced drug, code-named RE-021, in the first quarter of 2013. Shkreli is optimistic, based on conversations with the Food and Drug Administration, that this single study might be enough to obtain accelerated approval for the medicine in the U.S.
